# IMPACT of AspireSR® for VNS Therapy on Healthcare Resource Utilisation and Clinical Outcomes.

> **NCT05975931** · — · TERMINATED · sponsor: **LivaNova** · enrollment: 15 (actual)

## Conditions studied

- Epilepsy

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05975931
- **Lead sponsor:** LivaNova
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2022-01-20
- **Primary completion:** 2024-01-30
- **Final completion:** 2024-01-30
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** The decision to terminate was taken based on study team capacity not sufficient and alignment with the sponsor.
- **Last updated:** 2024-12-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05975931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05975931, "IMPACT of AspireSR® for VNS Therapy on Healthcare Resource Utilisation and Clinical Outcomes.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05975931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*